BACKGROUND AND PURPOSE: α-Melanocyte stimulating hormone (α-MSH) is an endogenously produced neuropeptide derived from the same precursor as adrenocorticotropic hormone. α-MSH has profound immunomodulatory properties and may also be neuroprotective. Nothing is known about α-MSH and changes in its plasma concentrations in patients with acute ischemic stroke. METHODS: In this prospective observational study, plasma concentrations of α-MSH, adrenocorticotropic hormone, cortisol, and interleukin 6 were assessed longitudinally over the course of 1 year after stroke onset in 111 patients. Logistic regression was used to the effect of initial plasma α-MSH, adrenocorticotropic hormone, cortisol, and interleukin 6 on long-term outcome. RESULTS: There was an early decrease in plasma α-MSH in patients with severe stroke (National Institutes of Health Stroke Scale≥17) that normalized over the course of the year; these same patients evidenced elevations in plasma cortisol and interleukin 6. Higher initial plasma α-MSH, but not adrenocorticotropic hormone, cortisol, or interleukin 6, was independently predictive of good long-term outcome. CONCLUSIONS: This research is the first to study endogenous changes in plasma α-MSH after stroke. The independent effect of early plasma α-MSH on stroke outcome, as well as a growing body of experimental data demonstrating improved stroke outcome with exogenous α-MSH administration, suggests a potential therapeutic role for α-MSH in the treatment of stroke.
BACKGROUND AND PURPOSE: α-Melanocyte stimulating hormone (α-MSH) is an endogenously produced neuropeptide derived from the same precursor as adrenocorticotropic hormone. α-MSH has profound immunomodulatory properties and may also be neuroprotective. Nothing is known about α-MSH and changes in its plasma concentrations in patients with acute ischemic stroke. METHODS: In this prospective observational study, plasma concentrations of α-MSH, adrenocorticotropic hormone, cortisol, and interleukin 6 were assessed longitudinally over the course of 1 year after stroke onset in 111 patients. Logistic regression was used to the effect of initial plasma α-MSH, adrenocorticotropic hormone, cortisol, and interleukin 6 on long-term outcome. RESULTS: There was an early decrease in plasma α-MSH in patients with severe stroke (National Institutes of Health Stroke Scale≥17) that normalized over the course of the year; these same patients evidenced elevations in plasma cortisol and interleukin 6. Higher initial plasma α-MSH, but not adrenocorticotropic hormone, cortisol, or interleukin 6, was independently predictive of good long-term outcome. CONCLUSIONS: This research is the first to study endogenous changes in plasma α-MSH after stroke. The independent effect of early plasma α-MSH on stroke outcome, as well as a growing body of experimental data demonstrating improved stroke outcome with exogenous α-MSH administration, suggests a potential therapeutic role for α-MSH in the treatment of stroke.
Authors: S Neidert; M Katan; P Schuetz; F Fluri; A Ernst; R Bingisser; L Kappos; S T Engelter; A Steck; B Müller; M Christ-Crain Journal: J Intern Med Date: 2011-03-01 Impact factor: 8.989
Authors: Kyra J Becker; Angela J Kalil; Pat Tanzi; Dannielle K Zierath; Anna V Savos; J Michael Gee; Jessica Hadwin; Kelly T Carter; Dean Shibata; Kevin C Cain Journal: Stroke Date: 2011-07-28 Impact factor: 7.914
Authors: Sandra Magnoni; Nino Stocchetti; Gualtiero Colombo; Andrea Carlin; Angelo Colombo; James M Lipton; Anna Catania Journal: J Neurotrauma Date: 2003-03 Impact factor: 5.269
Authors: Paul M Holloway; Pascal F Durrenberger; Marjan Trutschl; Urska Cvek; Dianne Cooper; A Wayne Orr; Mauro Perretti; Stephen J Getting; Felicity N E Gavins Journal: Arterioscler Thromb Vasc Biol Date: 2015-06-25 Impact factor: 8.311
Authors: Rajesh Kumar Goit; Tsz Chung Ng; Ka Cheung Tam; Jessica K W Tsang; Andrew W Taylor; Amy C Y Lo Journal: Neurochem Res Date: 2021-09-29 Impact factor: 3.996
Authors: Rune E Kuhre; Ida M Modvig; Sara L Jepsen; Hüsün S Kizilkaya; Cecilie Bæch-Laursen; Christopher A Smith; Frank Reimann; Fiona M Gribble; Mette M Rosenkilde; Jens J Holst Journal: Front Endocrinol (Lausanne) Date: 2021-08-05 Impact factor: 5.555
Authors: Amanda Jayne Barugh; Paul Gray; Susan Deborah Shenkin; Alasdair Maurice Joseph MacLullich; Gillian Elizabeth Mead Journal: J Neurol Date: 2014-01-30 Impact factor: 4.849
Authors: Eva-Verena Schaible; Arne Steinsträßer; Antje Jahn-Eimermacher; Clara Luh; Anne Sebastiani; Frida Kornes; Dana Pieter; Michael K Schäfer; Kristin Engelhard; Serge C Thal Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240